Nurix Therapeutics announced that CEO Arthur T. Sands will join fireside chats at major RBC and Jefferies healthcare conferences, while updated efficacy and safety data for its BTK degrader ...

Most drugs work by inhibition: they block a protein's activity but leave the protein itself intact. Targeted protein ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...

A preclinical study has developed a strategy that enables the forced elimination of proteins that help tumors survive ...

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of thalidomide ...